Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

주식 순위 #2014
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
주가
$446.50
마지막 동기화: 2026-10-19
시가총액
$10.32B
변동 (1일)
-0.72%
변동 (1년)
1.48%
국가
US
거래 Madrigal Pharmaceuticals, Inc. (MDGL)

카테고리

Healthcare
Madrigal Pharmaceuticals, Inc. (MDGL)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 25.60
Madrigal Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 25.60입니다. 2023년 말 기준 P/B 비율은 10.67였습니다.
Madrigal Pharmaceuticals, Inc.의 P/B 비율 기록 (2001 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 25.60 194.25%
2024 8.70 -18.43%
2023 10.67 -57.67%
2022 25.20 252.68%
2021 7.15 -0.16%
2020 7.16 112.52%
2019 3.37 -3.71%
2018 3.50 -43.30%
2017 6.17 189.53%
2016 2.13 5,020.19%
2015 0.04 -98.96%
2014 4.01 -47.11%
2013 7.58 6.16%
2012 7.14 -52.14%
2011 14.91 41.78%
2010 10.52 52.82%
2009 6.88 -296.01%
2008 -3.51 -140.19%
2007 8.74 -107.54%
2006 -115.85 -3,105.47%
2005 3.85 167.44%
2004 1.44 -44.21%
2003 2.58 0.00%
2002 0.00 -100.00%
2001 9.71 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.251 -75.58%
US
13.2547 -48.22%
US
4.208 -83.56%
AU
- -
CH
6.1824 -75.85%
NL